Similar articles

• Essential lessons in cardiogenic shock: epinephrine versus norepinephrine/dobutamine.

  Krenn L, Delle Karth G. Krenn L, et al. Crit Care Med. 2011 Mar;39(3):583-4. doi: 10.1097/CCM.0b013e318208e381. Crit Care Med. 2011. PMID: 21330855 No abstract available.
• Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study.

  Levy B, Perez P, Perny J, Thivilier C, Gerard A. Levy B, et al. Crit Care Med. 2011 Mar;39(3):450-5. doi: 10.1097/CCM.0b013e3181ffe0eb. Crit Care Med. 2011. PMID: 21037469 Clinical Trial.
• [Drug therapy in cardiogenic shock].

  Wenger R. Wenger R. Int J Clin Pharmacol. 1973 Apr;7(2):127-31. Int J Clin Pharmacol. 1973. PMID: 4147221 German. No abstract available.
• Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.

  Liao X, Qian L, Zhang S, Chen X, Lei J. Liao X, et al. J Healthc Eng. 2020 Jul 31;2020:8862256. doi: 10.1155/2020/8862256. eCollection 2020. J Healthc Eng. 2020. PMID: 32802302 Free PMC article. Review.
• Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.

  Goldberg LI, Hsieh YY, Resnekov L. Goldberg LI, et al. Prog Cardiovasc Dis. 1977 Jan-Feb;19(4):327-40. doi: 10.1016/0033-0620(77)90007-x. Prog Cardiovasc Dis. 1977. PMID: 12536 Review. No abstract available.